Search

Researchers at Shenyang Pharmaceutical University in China have discovered a new method to enhance the effectiveness of cancer chemotherapy while reducing off-target toxicity. They have developed a redox-sensitive prodrug of podophyllotoxin (PPT) that can be combined with a natural compound called BL-193 to create a stable nanoassembly. This combination acts as a chemosensitizer, allowing for ultra-low-dose chemotherapy with potent antitumor responses. The study offers a novel approach to magnify the benefits of chemotherapy in cancer treatment. [Extracted from the article]

This document provides information about a Phase II/III clinical trial being conducted in China to test the effectiveness of Brentuximab vedotin (Bv) in the treatment of newly diagnosed classical Hodgkin lymphoma (cHL) in children, adolescents, and young adults. The trial aims to increase the early assessment complete response rate and reduce the proportion of patients receiving radiation therapy. The trial is expected to be completed by November 2029. The document also includes information on the drugs and study arms used in the treatment of Hodgkin lymphoma, as well as links to relevant publications on the topic. [Extracted from the article]

A study conducted by researchers at Fujian Medical University in Fuzhou, China, explored the efficacy and safety of a stem cell mobilization strategy for patients with relapsed or refractory aggressive lymphoma. The study analyzed the outcomes of chemo-mobilization based on a combination of Etoposide and Cytarabine, along with G-CSF mobilization, in 98 patients. The results showed that the majority of patients achieved adequate mobilization and successful hematopoietic recovery, with acceptable hematological toxicity and no mobilization-related mortality. The researchers concluded that this mobilization regimen could be an option for patients with relapsed or refractory lymphoma, particularly those undergoing salvage autologous stem cell transplantation therapy. [Extracted from the article]

A patent application titled "Combination Of Bi853520 With Chemotherapeutic Drugs" has been published online. The inventors propose the use of BI853520, a specific compound, in combination with chemotherapeutic drugs for the treatment of various types of tumors, including breast cancer, lung cancer, colon cancer, ovarian cancer, and more. The inventors aim to improve the efficacy of chemotherapy and overcome drug resistance, which is a major challenge in cancer treatment. The patent application provides detailed information on the structure of BI853520 and its potential use in combination with different chemotherapeutic drugs. [Extracted from the article]

This document provides information about a clinical trial for patients with multiple myeloma who require autologous stem cell transplantation (ASCT). The trial compares two treatment regimens: the CG regimen, which combines cyclophosphamide and G-CSF, and the EAP regimen, which combines etoposide, cytarabine, and PEG-rhG-CSF. The trial is currently recruiting participants in China and aims to enroll a total of 99 patients. The document also includes eligibility criteria and contact information for the study. [Extracted from the article]

This document provides information about a clinical trial for the treatment of non-Hodgkin's lymphoma. The trial aims to evaluate different chemotherapy mobilization regimens for autologous stem cell transplantation. The study will enroll 99 subjects and is currently recruiting participants. The trial will compare disease-specific chemotherapy regimens, such as CHOP and Hyper-CVAD, with an experimental regimen called EAP, a combination therapy that includes etoposide, cytarabine, and PEG-rhG-CSF. The trial will take place in China and is expected to be completed by December 2026. [Extracted from the article]

A recent study conducted at Fujian Cancer Hospital in China evaluated the efficacy and safety of camrelizumab, a humanized monoclonal antibody, combined with neoadjuvant chemotherapy in patients with neuroendocrine carcinoma of the cervix (NECC). The study found that the combination treatment achieved an overall response rate of 100%, with complete remission observed in 8.33% of patients and partial remission in 91.67% of patients. The treatment outperformed traditional therapies in terms of efficacy and had manageable toxicity levels. The study is ongoing and aims to assess secondary objectives such as disease control rate, progression-free survival, and overall survival. [Extracted from the article]

A clinical trial, NCT06504030, is currently underway at The First Affiliated Hospital of Soochow University to evaluate the effectiveness and safety of a modified DEP regimen for the treatment of hemophagocytic lymphohistiocytosis (HLH). The trial aims to enroll 20 participants who meet the diagnosis criteria for HLH and are between the ages of 1 and 70. The treatment involves a combination of drugs, including doxorubicin, etoposide, and methylprednisolone, along with other medications depending on the type of HLH. The trial is in the interventional phase and is open to individuals of all genders who provide informed consent. [Extracted from the article]

A study conducted at Hokkaido University Hospital in Sapporo, Japan, evaluated the efficacy of adding aprepitant (APR) to palonosetron (PALO) and dexamethasone (DEX) in carboplatin (CBDCA) and etoposide (ETP) therapy. The study found that combining APR with PALO and DEX did not improve the complete response (CR) rate in CBDCA + ETP therapy. The research suggests that the additional efficacy of APR in CBDCA-containing treatment remains controversial, and data on multiple-day treatments are limited. [Extracted from the article]

This document provides information about a clinical trial, NCT06478264, that is currently being conducted to evaluate the effectiveness and safety of a treatment for small cell carcinoma of the esophagus. The trial involves the use of a drug called Adebrelimab, along with chemotherapy drugs Cisplatin and Carboplatin, and radiotherapy. The trial is not yet recruiting participants and aims to enroll 40 individuals between the ages of 18 and 75. The document includes contact information for the primary investigator and lists the eligibility criteria for participation in the trial. [Extracted from the article]

A study conducted at Niigata University Graduate School of Medical and Dental Sciences in Japan examined the safety and efficacy of durvalumab, carboplatin, and etoposide as a treatment for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS). The study enrolled 57 patients with PS 2 or 3, and the primary endpoint was tolerability. The results showed that 68% of PS 2 patients and 50% of PS 3 patients completed four cycles of treatment. The overall response rates were 52% for PS 2 and 45% for PS 3, and the median progression-free survival was 4.7 months for PS 2 and 5.1 months for PS 3. The study concluded that the combination therapy of durvalumab, carboplatin, and etoposide showed promising efficacy and tolerability for ES-SCLC patients with a poor PS. [Extracted from the article]

A recent study conducted by the Bulgarian Academy of Sciences (BAS) has focused on mitotic inhibitors, which are drugs that target cancer cells by inhibiting their ability to divide. The researchers synthesized and characterized two new compounds with potential application as topoisomerase II (TOP2) inhibitors, which are enzymes involved in altering DNA topology. The compounds showed a higher binding affinity towards TOP2 but lower antiproliferative activity compared to the reference inhibitor etoposide. This research provides valuable insights into the development of isoform-specific TOP2 inhibitors for cancer treatment. [Extracted from the article]

A study conducted at Kindai University in Osaka, Japan, aimed to identify risk factors for febrile neutropenia (FN) in patients with small-cell lung cancer (SCLC) receiving carboplatin plus etoposide therapy. The study found that the co-administration of proton pump inhibitors (PPIs) or potassium-competitive acid blockers (PCABs) and a low body mass index (BMI) were significantly associated with FN. Patients with both factors had a higher frequency of FN compared to those without the factors. This research provides valuable insights into the risk factors for FN in SCLC patients undergoing this specific chemotherapy regimen. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Warsaw in Poland focused on the antiretroviral drug podophyllotoxin (PPT) and its potential therapeutic effects. PPT is currently used topically to treat anogenital warts due to its systemic toxicity. The study examined the ultrastructural changes induced by PPT on HaCaT keratinocytes and tracked its intracellular localization using a fluorescent derivative. The researchers found that PPT had a time-dependent cytotoxic effect on the cells, causing disruptions in the endoplasmic reticulum and mitochondria. They also discovered that the fluorescent derivative of PPT formed a stable complex with tubulin, making it a useful tool for tracking intracellular PPT binding and trafficking. [Extracted from the article]

A research study conducted at Southmead Hospital in Bristol, United Kingdom, has investigated the role of insulin-like growth factor binding protein-2 (IGFBP-2) in mediating chemoresistance in breast cancer cells. The study found that IGFBP-2 acts as a survival factor for breast cancer cells and enhances the DNA repair mechanism. The research involved experiments with different breast cancer cell lines and the use of etoposide, a chemotherapy drug. The findings contribute to a better understanding of breast cancer and its resistance to chemotherapy. The study was supported by Cancer Research UK and the Saudi Arabian Ministry of Higher Education. [Extracted from the article]

This document provides information about a clinical trial, NCT06462105, which aims to study the treatment of small cell lung cancer (SCLC). SCLC is a highly malignant tumor with a high mortality rate, and the trial aims to compare the efficacy and safety of two different treatment regimens for first-line treatment of extensive stage SCLC. The study is not yet recruiting participants, and the estimated completion date is June 30, 2027. The document also includes keywords related to the study, such as antineoplastics, lung cancer, chemotherapy, and quality of life. [Extracted from the article]

A recent study conducted by researchers at Arak University in Iran investigated the effects of the chemotherapy drug etoposide on sperm parameters in male mice. Etoposide is known to cause fertility problems in children with cancer. The study found that etoposide significantly decreased sperm count, motility, viability, tail length, and normal morphology, as well as total antioxidant capacity, while increasing levels of malondialdehyde. However, when pentoxifylline, an antioxidant, was administered alongside etoposide, it mitigated these harmful effects. The study suggests that etoposide induces damage through apoptosis, oxidative stress, and lipid peroxidation, and pentoxifylline's antioxidant properties help reduce oxidative stress. [Extracted from the article]

A recent study conducted by researchers from Ahvaz Jundishapur University of Medical Sciences in Iran explores the potential of combining etoposide (ETO), a chemotherapy drug, with quercetin (QC), a phytochemical, to enhance the treatment of breast cancer. The researchers developed quercetin-loaded solid lipid nanoparticles (QC-SLNs) for efficient delivery and found that when combined with ETO, the QC-SLNs significantly inhibited the proliferation of breast cancer cells and increased apoptosis. The study suggests that this combination therapy has the potential to overcome chemoresistance observed in ETO-resistant breast cancer. Further research is needed to explore the efficacy of this strategy in breast cancer treatment. [Extracted from the article]

Researchers from Wuhan University in China have developed a new method to enhance the anticancer efficacy of the drug etoposide by depleting glutathione levels. Glutathione is an antioxidant that contributes to drug resistance in cancer therapy. The researchers synthesized a biocompatible acid-responsive polycarbonate containing cinnamaldehyde, a potent glutathione-depleting agent, and encapsulated etoposide in nanoparticles. In vitro and in vivo experiments demonstrated that the new formulation, called ETS@PCA, exhibited superior cytotoxicity and enhanced tumor inhibitory effects compared to free etoposide. This research provides a potential strategy to overcome drug resistance in cancer treatment. [Extracted from the article]

Researchers at the Cancer Research Center in Salamanca, Spain have published a new report on antiretrovirals. The study focused on the compound podophyllic aldehyde, a cyclolignan derived from the natural product podophyllotoxin. The researchers found that podophyllic aldehyde exhibited increased cytotoxicity and more successful cell cycle blocking compared to the FDA-approved drug etoposide, another podophyllotoxin derivative. The compound also showed a selective antimitotic mechanism of action in certain tumor cell lines. These findings suggest that podophyllic aldehyde has potential as a new antitumor therapy and should be further studied and analyzed. [Extracted from the article]

A recent study conducted by researchers at the Instituto Nacional de Pediatria explored the effects of oligoelements, such as cytarabine and etoposide, on dopamine levels and oxidative damage in the brains of young Wistar rats. The study found that the combination of oligoelements and cytarabine increased dopamine in the striatum but decreased it in the cerebellum/medulla-oblongata, while the combination of oligoelements and etoposide reduced lipid peroxidation. These findings suggest that supplementation with oligoelements may modify the effects of certain cancer treatments and could potentially be used as therapeutic targets for patients with cancer. [Extracted from the article]

A recent study conducted by researchers at the Department of Pharmacy evaluated the cost-effectiveness of different treatment options for extensive-stage small cell lung cancer (ES-SCLC). The study found that adding tremelimumab to durvalumab plus etoposide-platinum (DEP) did not significantly improve outcomes compared to etoposide-platinum (EP). DEP and DTEP were not considered cost-effective options compared to EP from a third-party payer perspective in the United States. The study concluded that DEP was dominated when compared to DTEP. [Extracted from the article]

A recent study conducted at Tongji University in Shanghai, China, explored the use of layered double hydroxide (LDH) nanoparticles as a potential treatment for breast cancer in pregnant women. The researchers aimed to find a safe and effective cancer therapeutic agent that would protect both the mother and the developing fetus. The study found that LDH@VP16, a combination of LDH and etoposide (VP16), showed promising results in inhibiting tumor growth while protecting embryonic development. This research provides a new perspective on developing antineoplastic agents during pregnancy and may have implications for future treatments. [Extracted from the article]

A recent study conducted in Salamanca, Spain, focused on the chemomodulation of podophyllotoxin, a cyclolignan natural product, to develop more effective chemotherapeutic agents. The researchers synthesized derivatives of podophyllic aldehyde and evaluated their potency and selectivity against various cancer cells. The results showed that compounds with the lactone ring of podophyllotoxin were the most potent, while the a,b-unsaturated aldehyde was necessary for inducing selectivity in these cyclolignans. The study suggests that the g-lactone ring is crucial for potency. Further information on this research can be found in the journal article "Cytotoxic Cyclolignans Obtained by the Enlargement of the Cyclolignan Skeleton of Podophyllic Aldehyde, a Selective Podophyllotoxin-Derived Cyclolignan." [Extracted from the article]

A recent report from Newcastle University in the United Kingdom discusses the potential benefits of myeloperoxidase (MPO) inhibition in protecting bone marrow cells from DNA damage caused by the anti-cancer drug etoposide. Etoposide is known to be associated with cases of secondary acute myeloid leukemia due to its DNA damaging properties. The researchers suggest that MPO inhibitors, which are currently being developed as anti-inflammatory agents, could potentially be repurposed to reduce the risk of therapy-related leukemia while preserving the anti-cancer efficacy of etoposide treatment. This research provides new insights into the potential use of MPO inhibitors in cancer therapy. [Extracted from the article]

A study conducted by the Bombay College of Pharmacy in Mumbai, India, has developed a new treatment approach for retinoblastoma, a type of eye cancer. The researchers created biodegradable microparticles loaded with carboplatin and etoposide, which showed greater anti-cancer effects compared to the plain drug mixture in cell lines. In an orthotropic mouse model, the microparticles demonstrated a significant reduction in tumor burden and an increased apoptotic effect. This research provides promising evidence for the efficacy of the developed microparticles as a potential treatment for retinoblastoma. [Extracted from the article]

A recent study conducted at Shandong University in China has developed a nanoporous-gold-based electrochemical sensor for the rapid detection of the anti-tumor drug etoposide in biological samples. Etoposide is commonly used in cancer therapy, but current detection methods are expensive and complicated. The nanoporous gold sensor showed a sensitive response to etoposide, with a linear relationship between concentration and current. The sensor also demonstrated good performance in terms of sensitivity, reproducibility, and specificity when tested in serum, urine, and fermentation broth. This research provides a promising tool for the detection of etoposide in biological samples. [Extracted from the article]

A recent study conducted at the University of Pennsylvania explored the potential benefits of co-releasing etoposide and zosuquidar, which are P-glycoprotein (P-gp) inhibitors, from amorphous solid dispersions (ASDs) to increase the oral bioavailability of etoposide. The researchers prepared ASDs of etoposide and zosuquidar in different polymers and found that the release of etoposide was fastest from polyvinylpyrrolidone (PVP), followed by hydroxypropylmethyl cellulose (HPMC) 5, and slowest from HPMC 4. In in vitro and in vivo studies, the co-administration of etoposide and zosuquidar in ASDs resulted in a significant increase in oral bioavailability compared to crystalline etoposide. The study suggests that simultaneous co-release of an amorphous P-gp substrate and inhibitor may be a promising formulation strategy to enhance the bioavailability of P-gp substrates. [Extracted from the article]

A recent study published in the Research Journal of Pharmacy and Technology examined the effects of whey preparation on intestinal mucositis in a rat model. The researchers administered a single dose of etoposide to induce mucositis and then administered whey preparation before and after the injection. They found that whey preparation was effective in reducing the levels of inflammatory markers and apoptosis caused by etoposide. The study suggests that whey preparation has the potential to minimize the harmful effects of etoposide on normal cells and prevent mucositis. [Extracted from the article]

This document provides information about a clinical trial in China for the treatment of limited-stage small cell lung cancer (SCLC). The trial aims to evaluate the effectiveness and safety of a new immunotherapeutic strategy that combines neoadjuvant chemotherapy with the antibodies toripalimab and JS004, along with etoposide and platinum chemotherapy. The trial is being conducted by Shanghai Pulmonary Hospital in Shanghai, China, and is expected to be completed by January 31, 2027. The goal of the trial is to achieve a higher complete pathological response rate for SCLC patients. [Extracted from the article]

A recent study conducted by researchers at D. Mendeleev University of Chemical Technology in Moscow, Russia, focuses on the use of colloidal delivery systems to enhance the effectiveness of etoposide, a chemotherapy drug used to treat various tumors. The study explores the use of nanoparticles and micelles made of synthetic and natural polymers as carriers for etoposide, which can improve its pharmacokinetic properties and increase its accumulation in tumors. The researchers also highlight the potential of stimuli-sensitive systems that respond to specific conditions in the tumor microenvironment to enhance the selectivity of the drug. The study was supported by the Russian Science Foundation and has been peer-reviewed. [Extracted from the article]

This document provides information about two clinical trials aimed at evaluating the safety and effectiveness of vaccines for preventing meningococcal meningitis. The first trial focuses on the ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in individuals aged 18-59 years. The trial is randomized and observer-blind, with participants receiving a single dose of the vaccine. The second trial evaluates the effectiveness of two different vaccines, MCV4 and MPSV4, in preventing the disease. The study will enroll 840 participants between the ages of 18 and 59, who have not received a meningococcal vaccine in the past three years. The estimated completion date for the trial is October 2024. [Extracted from the article]

A recent study conducted at the Department of Radiation Oncology in Dijon, France, examined the use of carboplatin and etoposide chemotherapy in the treatment of metastatic prostate cancer (mPC). The study analyzed the efficacy and tolerance of this chemotherapy in three different groups of mPC patients: those with primary small-cell neuroendocrine (PSC-NE) carcinoma, adenocarcinoma with neuroendocrine (NE) marker elevation, and adenocarcinoma without NE marker elevation. The results showed that the benefit/risk ratio of this chemotherapy was unfavorable in heavily pretreated adenocarcinoma patients due to poor response and high toxicity. The study suggests that PSC-NE and castration-resistant adenocarcinoma of the prostate should not be mixed. [Extracted from the article]

A study conducted at City University of Hong Kong has found that the chemotherapy drug Etoposide, used to treat lung cancer, may unintentionally lead to the development of antibiotic resistance in bacteria such as Pseudomonas aeruginosa. The researchers discovered that prolonged exposure to Etoposide caused oxidative stress and gene mutations in P. aeruginosa, resulting in acquired resistance to fluoroquinolone antibiotics. Furthermore, the study showed that these antibiotic-resistant bacteria could form biofilms that protected tumor cells from Etoposide and facilitated tumor progression. This research highlights the potential unintended consequences of chemotherapy on the development of antibiotic resistance in tumor-associated bacteria and suggests the need for novel anti-bacterial strategies in cancer treatment. [Extracted from the article]

A clinical trial, NCT06172296, is being conducted to test the effectiveness of adding dinutuximab to standard treatment for children with high-risk neuroblastoma. The trial will evaluate the combination of dinutuximab with chemotherapy, surgery, radiation, and stem cell transplantation. It aims to assess survival rates, response rates, adverse events, and other outcome measures. The trial is set to start in 2024 and is expected to be completed by 2029. This phase III trial aims to determine the effectiveness of adding dinutuximab to induction chemotherapy for the treatment of children with high-risk neuroblastoma. The trial will assess survival rates, response rates, toxicities, and explore biomarkers and markers of minimal residual disease. Various treatments and procedures, including radiation, dinutuximab, and scans, are involved in the study. The study is in Phase 3 and is designed as a randomized intervention. The primary purpose is treatment, and patients are followed up after completing the study treatment. The document provides a list of medications, procedures, and alternative names related to cancer treatment. It also provides a list of drugs, procedures, and alternative names for a clinical trial. The trial, known as ANBL2131, is being conducted by the National Cancer Institute (NCI) and aims to study the treatment of high-risk neuroblastoma in patients up to 30 years old. The trial is investigating various aspects of the disease, including genetics [Extracted from the article]

This document provides information about a clinical trial for the treatment of small cell lung carcinoma. The trial involves the use of a drug called Adebrelimab, as well as chemotherapy and radiation therapy. The trial is currently recruiting participants, with an estimated enrollment of 62 individuals. The study is being conducted in China and is expected to be completed by September 30, 2026. The eligibility criteria for participants are outlined, and the responsible party for the trial is Nanfang Hospital, Southern Medical University. [Extracted from the article]

A recent report from Georgetown University discusses the findings of a study on the treatment of extensive-stage small cell lung cancer (ES-SCLC) with atezolizumab plus carboplatin and etoposide. The study found that this treatment significantly improved overall survival and progression-free survival compared to a placebo. The researchers also explored patient and disease characteristics associated with long-term survival and the associations of differential gene expression and SCLC transcriptional subtypes with long-term survival. The study suggests that long-term survival is more likely with atezolizumab than with a placebo, confirming the treatment benefit of this regimen. [Extracted from the article]

A recent study conducted at Peking University People's Hospital explored the role of cytoreductive chemotherapy in the prognosis of patients with low-risk acute promyelocytic leukemia (APL). The study analyzed consecutive low-risk APL patients who received all-trans retinoic acid (ATRA) plus arsenic for induction and consolidation therapy. The results showed that cytoreductive chemotherapy had a dual effect of cytoreduction and prevention of relapse in low-risk APL. The study suggested that oral etoposide combined with ATRA and arsenic could be a regimen with low relapse, good tolerance, and convenience. A prospective, randomized, controlled study comparing oral etoposide with intravenous daunorubicin is currently underway. [Extracted from the article]

A recent study conducted by researchers at Louisiana State University Health Sciences Center-Shreveport analyzed the real-world data on chemotherapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The researchers obtained data from the FDA Adverse Events Report System (FAERS) and found that cyclophosphamide was the most common drug associated with MDS/AML, followed by lenalidomide and etoposide. The study also revealed that MDS/AML was more common with etoposide compared to cyclophosphamide or lenalidomide. The researchers emphasized the importance of discussing the risks and benefits of these drugs with patients before treatment planning. [Extracted from the article]

A recent study conducted at Indiana University School of Medicine examined the potential causes of severe adverse drug reactions (ADRs) associated with the use of etoposide, a topoisomerase II inhibitor used in cancer treatment. The study focused on the role of a hydrophilic polyethersulfone filter in increasing rates of pediatric etoposide infusion reactions. Through a multidisciplinary approach, researchers assessed the chemical structure of etoposide after passing through the filter and found no detectable differences. The study emphasizes the importance of collaboration among healthcare professionals to investigate serious ADRs. [Extracted from the article]

A recent study conducted at Ruijin Hospital in Shanghai, China, explored the use of pomalidomide in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) as a salvage regimen for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study found that the addition of pomalidomide to the RICE regimen was feasible and resulted in promising response rates, particularly in patients with MYD88 mutations. The maximum tolerated dose of pomalidomide was determined to be 2 mg. Further research is needed to evaluate the efficacy of this treatment regimen. [Extracted from the article]

A recent study conducted at the Tata Memorial Centre in Mumbai, India, examined the outcomes of patients with Primary CNS lymphoma (PCNSL) who were treated with a combination of methotrexate, temozolomide, and rituximab (MTR) induction followed by modified etoposide-cytarabine (EA) consolidation. The study found that this treatment approach was feasible and resulted in favorable outcomes in a real-world setting. Higher cumulative methotrexate dose and the use of EA consolidation were associated with better overall survival. These findings provide a viable treatment option for PCNSL patients in resource-limited settings. [Extracted from the article]

A patent has been issued for an immunotherapeutic method for treating lung cancer by administering a polypeptide that contains an epitope of hZP3. Lung cancer is a common and deadly form of cancer, with most cases diagnosed at an advanced stage. Current treatments include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies. The invention focuses on using the zona pellucida protein 3 (ZP3) as a target for immunotherapeutic strategies, as ZP3 has been found to be expressed in lung cancer cells. The method aims to reduce tumor growth, eradicate tumors, prevent metastasis, and increase survival. [Extracted from the article]

Researchers from Ahvaz Jundishapur University of Medical Sciences in Iran have conducted a study on the potential synergistic effects of combining the drugs etoposide and quercetin on liver cancer cells. The study found that the combination of these drugs resulted in reduced cell viability and increased apoptosis in HepG2 liver cancer cells. The researchers concluded that further studies on this combination could lead to a potential anticancer compound against hepatocellular carcinoma (HCC), the most common type of liver cancer worldwide. This research has been peer-reviewed and published in Hepatitis Monthly. [Extracted from the article]